CoChat
Sign Up
Cited by 219Smoking Behavior and CessationSubstance Abuse Treatment and OutcomesNicotinic Acetylcholine Receptors Study

Current advances in research in treatment and recovery: Nicotine addiction

Open access
Prochaska, Judith J., Benowitz, Neal L.·2019·Science Advances
DOI 10.1126/sciadv.aay9763PMC PMC6795520
Open this paper in CoChat — free accountOpen PDF

Abstract

This review covers the changing tobacco product marketplace and evidence-based approaches to prevent and treat nicotine addiction.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciadv.aay9763

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The amount of nicotine a human absorbs is 1-1.5 mg/cigarette and 3.6 mg/portion of oral snuff.

    “The amount of nicotine a human absorbs has been reported to be 1–1.5 mg/cigarette 11 and 3.6 mg/portion of oral snuff. 12”

    From Decreased sperm counts in Swedish users of oral tobacco (2022) · cites this paper as [11]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 178

  1. [2]Jha P., Peto R., Global effects of smoking, of quitting, and of taxing tobacco. N. Engl. J. Med. 370, 60– 68 (2014). 24382066
  2. [6]Xu X., Bishop E. E., Kennedy S. M., Simpson S. A., Pechacek T. F., Annual healthcare spending attributable to cigarette smoking: An update. Am. J. Prev. Med. 48, 326– 333 (2015). 25498551 PMC4603661
  3. [8]Benowitz N. L., Nicotine addiction. N. Engl. J. Med. 362, 2295– 2303 (2010). 20554984 PMC2928221
  4. [9]R. N. Proctor, The Golden Holocaust (University of California Press, 2011).
  5. [10]Fanshawe T. R., Halliwell W., Lindson N., Aveyard P., Livingstone-Banks J., Hartmann-Boyce J., Tobacco cessation interventions for young people. Cochrane Database Syst. Rev. 11, CD003289 (2017). 29148565 PMC6486118
  6. [11]Wang T. W., Asman K., Gentzke A. S., Cullen K. A., Holder-Hayes E., Reyes-Guzman C., Jamal A., Neff L., King B. A., Tobacco product use among adults—United States, 2017. Morb. Mortal. Wkly. Rep. 67, 1225– 1232 (2018). PMC6223953 30408019
  7. [12]Jamal A., Phillips E., Gentzke A. S., Homa D. M., Babb S. D., King B. A., Neff L. J., Current cigarette smoking among adults—United States, 2016. Morb. Mortal. Wkly. Rep. 67, 53– 59 (2018). PMC5772802 29346338
  8. [13]Gentzke A. S., Creamer M., Cullen K. A., Ambrose B. K., Willis G., Jamal A., King B. A., Vital signs: Tobacco product use among middle and high school students—United States, 2011-2018. Morb. Mortal. Wkly. Rep. 68, 157– 164 (2019). PMC6375658 30763302
  9. [16]Perry C. L., Creamer M. R., Chaffee B. W., Unger J. B., Sutfin E. L., Kong G., Shang C., Clendennen S. L., Krishnan-Sarin S., Pentz M. A., Research on youth and young adult tobacco use, 2013–2018, from the Food and Drug Administration–National Institutes of Health Tobacco Centers of Regulatory Science. Nicotine Tob. Res., (2019). PMC7457341 31127298
  10. [18]Courtemanche C. J., Palmer M. K., Pesko M. F., Influence of the flavored cigarette ban on adolescent tobacco use. Am. J. Prev. Med. 52, e139– e146 (2017). 28081999 PMC5401634
  11. [21]Choi K., Inoue-Choi M., McNeel T. S., Freedman N. D., Mortality risks of dual- and poly-tobacco product users in the United States. Am. J. Epidemiol. 2019, kwz143 (2019). PMC8895390 31225859
  12. [22]Choi K., Sabado M., El-Toukhy S., Vogtmann E., Freedman N. D., Hatsukami D., Tobacco product use patterns, and nicotine and tobacco-specific nitrosamine exposure: NHANES 1999–2012. Cancer Epidemiol. Biomakers Prev. 26, 1525– 1530 (2017). PMC5626596 28710077
  13. [23]Kalkhoran S., Grana R. A., Neilands T. B., Ling P. M., Dual use of smokeless tobacco or E-cigarettes with cigarettes and cessation. Am. J. Health Behav. 39, 277– 284 (2015). 25564840 PMC4472731
  14. [24]The National Academies of Sciences, Engineering, and Medicine, Public Health Consequences of E-Cigarettes (National Academies Press, 2018). 29894118
  15. [25]Berry K. M., Fetterman J. L., Benjamin E. J., Bhatnagar A., Barrington-Trimis J. L., Leventhal A. M., Stokes A., Association of electronic cigarette use with subsequent initiation of tobacco cigarettes in US youths. JAMA Netw. Open 2, e187794 (2019). 30707232 PMC6484602
  16. [26]Barrington-Trimis J. L., Kong G., Leventhal A. M., Liu F., Mayer M., Cruz T. B., Krishnan-Sarin S., McConnell R., E-cigarette use and subsequent smoking frequency among adolescents. Pediatrics 142, e20180486 (2018). 30397165 PMC6312103
  17. [27]Vogel E. A., Prochaska J. J., Ramo D. E., Andres J., Rubinstein M. L., Adolescents’ E-cigarette use: Increases in frequency, dependence, and nicotine exposure over 12 months. J. Adolesc. Health 64, 770– 775 (2019). 31122507 PMC6538303
  18. [28]E. A. Vogel, J. J. Prochaska, M. L. Rubinstein, Measuring E-Cigarette Addiction Among Adolescents (BMJ Publishing Group Ltd., 2019). PMC7738215 31079033
  19. [30]Institute of Medicine, Committee on Preventing Nicotine Addiction in Children and Youths, The nature of nicotine addiction, in Growing Up Tobacco Free: Preventing Nicotine Addiction in Children and Youths, B. S. Lynch, R. J. Bonnie, Eds. (National Academies Press, 1994). 25144107
  20. [32]E. E. Omaiye, K. J. McWhirter, W. Luo, J. F. Pankow, P. Talbot, Toxicity of JUUL fluids and aerosols correlates strongly with nicotine and some flavor chemical concentrations. bioRxiv 490607 [Preprint]. 9 December 2018. 10.1101/490607. PMC6579667 30896936 · DOI
  21. [33]Benowitz N. L., Clinical pharmacology of nicotine: Implications for understanding, preventing, and treating tobacco addiction. Clin. Pharmacol. Ther. 83, 531– 541 (2008). 18305452
  22. [34]Benowitz N. L., Hukkanen J., Jacob P. III, Nicotine chemistry, metabolism, kinetics and biomarkers. Handb. Exp. Pharmacol. 192, 29– 60 (2009). PMC2953858 19184645
  23. [35]Allenby C. E., Boylan K. A., Lerman C., Falcone M., Precision medicine for tobacco dependence: Development and validation of the nicotine metabolite ratio. J. Neuroimmune Pharmacol. 11, 471– 483 (2016). 26872457 PMC5479354
  24. [36]Fowler C. D., Turner J. R., Imad Damaj M., Molecular mechanisms associated with nicotine pharmacology and dependence. Handb. Exp. Pharmacol., (2019). 31267166
  25. [38]Li X., Semenova S., D’Souza M. S., Stoker A. K., Markou A., Involvement of glutamatergic and GABAergic systems in nicotine dependence: Implications for novel pharmacotherapies for smoking cessation. Neuropharmacology 76 (Pt. B), 554– 565 (2014). 23752091 PMC3830589
  26. [39]Kishioka S., Kiguchi N., Kobayashi Y., Saika F., Nicotine effects and the endogenous opioid system. J. Pharmacol. Sci. 125, 117– 124 (2014). 24882143
  27. [40]Kohut S. J., Interactions between nicotine and drugs of abuse: A review of preclinical findings. Am. J. Drug Alcohol Abuse 43, 155– 170 (2017). 27589579 PMC5602608
  28. [41]Mineur Y. S., Picciotto M. R., Genetics of nicotinic acetylcholine receptors: Relevance to nicotine addiction. Biochem. Pharmacol. 75, 323– 333 (2008). 17632086 PMC2212607
  29. [42]Champtiaux N., Han Z.-Y., Bessis A., Rossi F. M., Zoli M., Marubio L., McIntosh J. M., Changeux J.-P., Distribution and pharmacology of α6-containing nicotinic acetylcholine receptors analyzed with mutant mice. J. Neurosci. 22, 1208– 1217 (2002). 11850448 PMC6757563
  30. [43]Bierut L. J., Stitzel J. A., Wang J. C., Hinrichs A. L., Grucza R. A., Xuei X., Saccone N. L., Saccone S. F., Bertelsen S., Fox L., Horton W. J., Breslau N., Budde J., Cloninger C. R., Dick D. M., Foroud T., Hatsukami D., Hesselbrock V., Johnson E. O., Kramer J., Kuperman S., Madden P. A., Mayo K., Nurnberger J. Jr., Pomerleau O., Porjesz B., Reyes O., Schuckit M., Swan G., Tischfield J. A., Edenberg H. J., Rice J. P., Goate A. M., Variants in nicotinic receptors and risk for nicotine dependence. Am. J. Psychiatry 165, 1163– 1171 (2008). 18519524 PMC2574742
  31. [44]Henderson B. J., Lester H. A., Inside-out neuropharmacology of nicotinic drugs. Neuropharmacology 96, 178– 193 (2015). 25660637 PMC4486611
  32. [45]Kenny P. J., Tobacco dependence, the insular cortex and the hypocretin connection. Pharmacol. Biochem. Behav. 97, 700– 707 (2011). 20816891 PMC3011037
  33. [46]Abdolahi A., Williams G. C., Benesch C. G., Wang H. Z., Spitzer E. M., Scott B. E., Block R. C., van Wijngaarden E., Immediate and sustained decrease in smoking urges after acute insular cortex damage. Nicotine Tob. Res. 19, 756– 762 (2017). 28199722 PMC5896541
  34. [48]Lewis A., Miller J. H., Lea R. A., Monoamine oxidase and tobacco dependence. Neurotoxicology 28, 182– 195 (2007). 16859748
  35. [50]Heatherton T. F., Kozlowski L. T., Frecker R. C., Rickert W., Robinson J., Measuring the heaviness of smoking: Using self-reported time to the first cigarette of the day and number of cigarettes smoked per day. Br. J. Addict. 84, 791– 799 (1989). 2758152
  36. [51]Muhammad-Kah R. S., Hayden A. D., Liang Q., Frost-Pineda K., Sarkar M., The relationship between nicotine dependence scores and biomarkers of exposure in adult cigarette smokers. Regul. Toxicol. Pharmacol. 60, 79– 83 (2011). 21342662
  37. [52]Siahpush M., Borland R., Yong H.-H., Sociodemographic and psychosocial correlates of smoking-induced deprivation and its effect on quitting: Findings from the International Tobacco Control Policy Evaluation Survey. Tob. Control 16, e2 (2007). 17400932 PMC2598473
  38. [53]Hymowitz N., Cummings K. M., Hyland A., Lynn W. R., Pechacek T. F., Hartwell T. D., Predictors of smoking cessation in a cohort of adult smokers followed for five years. Tob. Control 6 (suppl. 2), S57– S62 (1997). PMC1766209 9583654
  39. [54]Schnoll R. A., Goren A., Annunziata K., Suaya J. A., The prevalence, predictors and associated health outcomes of high nicotine dependence using three measures among US smokers. Addiction 108, 1989– 2000 (2013). 23795712
  40. [55]Gu F., Cheung L. C., Freedman N. D., Katki H. A., Caporaso N. E., Potential impact of including time to first cigarette in risk models for selecting ever-smokers for lung cancer screening. J. Thorac. Oncol. 12, 1646– 1653 (2017). 28818607 PMC5662032
  41. [56]Chen J., Loukola A., Gillespie N. A., Peterson R., Jia P., Riley B., Maes H., Dick D. M., Kendler K. S., Damaj M. I., Miles M. F., Zhao Z., Li M. D., Vink J. M., Minica C. C., Willemsen G., Boomsma D. I., Qaiser B., Madden P. A. F., Korhonen T., Jousilahti P., Hallfors J., Gelernter J., Kranzler H. R., Sherva R., Farrer L., Maher B., Vanyukov M., Taylor M., Ware J. J., Munafo M. R., Lutz S. M., Hokanson J. E., Gu F., Landi M. T., Caporaso N. E., Hancock D. B., Gaddis N. C., Baker T. B., Bierut L. J., Johnson E. O., Chenoweth M., Lerman C., Tyndale R., Kaprio J., Chen X., Genome-wide meta-analyses of FTND and TTFC phenotypes. Nicotine Tob. Res., (2019). PMC7249921 31294817
  42. [57]Schnoll R. A., George T. P., Hawk L., Cinciripini P., Wileyto P., Tyndale R. F., The relationship between the nicotine metabolite ratio and three self-report measures of nicotine dependence across sex and race. Psychopharmacology 231, 2515– 2523 (2014). 24402139 PMC4040302
  43. [59]Borland R., Yong H.-H., O’Connor R. J., Hyland A., Thompson M. E., The reliability and predictive validity of the Heaviness of Smoking Index and its two components: Findings from the International Tobacco Control Four Country study. Nicotine Tob. Res. 12, S45– S50 (2010). 20889480 PMC3307335
  44. [60]Heatherton T. F., Kozlowski L. T., Frecker R. C., Fagerström K. O., The Fagerström test for nicotine dependence: A revision of the Fagerström tolerance questionnaire. Br. J. Addict. 86, 1119– 1127 (1991). 1932883
  45. [61]Foulds J., Veldheer S., Yingst J., Hrabovsky S., Wilson S. J., Nichols T. T., Eissenberg T., Development of a questionnaire for assessing dependence on electronic cigarettes among a large sample of ex-smoking E-cigarette users. Nicotine Tob. Res. 17, 186– 192 (2015). 25332459 PMC4838001
  46. [62]American Psychiatric Association, Diagnostic and Statıstıcal Manual of Mental Dısorders (American Psychiatric Association, ed. 5, 2013), pp. 461–481.
  47. [63]Siahpush M., Shaikh R. A., Cummings K. M., Hyland A., Dodd M., Carlson L., Kessler A. S., Meza J., Wan N., Wakefield M., The association of point-of-sale cigarette marketing with cravings to smoke: Results from a cross-sectional population-based study. Tob. Control 25, 402– 405 (2016). 26024797 PMC4663166
  48. [64]Nonnemaker J., Kim A., Shafer P., Loomis B., Hill E., Holloway J., Farrelly M., Influence of point-of-sale tobacco displays and plain black and white cigarette packaging and advertisements on adults: Evidence from a virtual store experimental study. Addict. Behav. 56, 15– 22 (2016). 26785362
  49. [65]Shmueli D., Prochaska J. J., Glantz S. A., Effect of smoking scenes in films on immediate smoking: A randomized controlled study. Am. J. Prev. Med. 38, 351– 358 (2010). 20307802 PMC2854161
  50. [66]Giedd J. N., Blumenthal J., Jeffries N. O., Castellanos F. X., Liu H., Zijdenbos A., Paus T., Evans A. C., Rapoport J. L., Brain development during childhood and adolescence: A longitudinal MRI study. Nat. Neurosci. 2, 861– 863 (1999). 10491603
  51. [68]Yuan M., Cross S. J., Loughlin S. E., Leslie F. M., Nicotine and the adolescent brain. J. Physiol. 593, 3397– 3412 (2015). 26018031 PMC4560573
  52. [71]Robinson M. L., Berlin I., Moolchan E. T., Tobacco smoking trajectory and associated ethnic differences among adolescent smokers seeking cessation treatment. J. Adolesc. Health 35, 217– 224 (2004). 15313503
  53. [72]Grant B. F., Age at smoking onset and its association with alcohol consumption and DSM-IV alcohol abuse and dependence: Results from the national longitudinal alcohol epidemiologic survey. J. Subst. Abuse 10, 59– 73 (1998). 9720007
  54. [73]Taioli E., Wynder E. L., Effect of the age at which smoking begins on frequency of smoking in adulthood. N. Engl. J. Med. 325, 968– 969 (1991). 1881424
  55. [75]Hu M.-C., Griesler P. C., Schaffran C., Wall M. M., Kandel D. B., Trajectories of criteria of nicotine dependence from adolescence to early adulthood. Drug Alcohol Depend. 125, 283– 289 (2012). 22513378 PMC3592202
  56. [76]Volkow N. D., Altered pathways: Drug abuse and age of onset. Addict Prof. 26, 29 (2006).
  57. [77]Breslau N., Peterson E. L., Smoking cessation in young adults: Age at initiation of cigarette smoking and other suspected influences. Am. J. Public Health 86, 214– 220 (1996). 8633738 PMC1380330
  58. [78]Chassin L., Presson C. C., Rose J. S., Sherman S. J., The natural history of cigarette smoking from adolescence to adulthood: Demographic predictors of continuity and change. Health Psychol. 15, 478– 484 (1996). 8973929
  59. [79]Guydish J., Tajima B., Pramod S., Le T., Gubner N. R., Campbell B., Roman P., Use of multiple tobacco products in a national sample of persons enrolled in addiction treatment. Drug Alcohol Depend. 166, 93– 99 (2016). 27449271 PMC4983463
  60. [82]Prochaska J. J., Hall S. M., Bero L. A., Tobacco use among individuals with schizophrenia: What role has the tobacco industry played? Schizophr. Bull. 34, 555– 567 (2007). 17984298 PMC2632440
  61. [83]Windle M., Windle R. C., Depressive symptoms and cigarette smoking among middle adolescents: Prospective associations and intrapersonal and interpersonal influences. J. Consult. Clin. Psychol. 69, 215– 226 (2001). 11393599
  62. [84]Zevin S., Benowitz N. L., Drug interactions with tobacco smoking. Clin. Pharmacokinet. 36, 425– 438 (1999). 10427467
  63. [85]Clarke D. E., Eaton W. W., Petronis K. R., Ko J. Y., Chatterjee A., Anthony J. C., Increased risk of suicidal ideation in smokers and former smokers compared to never smokers: Evidence from the Baltimore ECA follow-up study. Suicide Life Threat. Behav. 40, 307– 318 (2010). 20822357 PMC2936702
  64. [86]McDermott M. S., Marteau T. M., Hollands G. J., Hankins M., Aveyard P., Change in anxiety following successful and unsuccessful attempts at smoking cessation: Cohort study. Br. J. Psychiatry 202, 62– 67 (2013). 23284151
  65. [87]Kahler C. W., Spillane N. S., Busch A. M., Leventhal A. M., Time-varying smoking abstinence predicts lower depressive symptoms following smoking cessation treatment. Nicotine Tob. Res. 13, 146– 150 (2010). 21106663 PMC3028190
  66. [88]McFall M., Saxon A. J., Malte C. A., Chow B., Bailey S., Baker D. G., Beckham J. C., Boardman K. D., Carmody T. P., Joseph A. M., Smith M. W., Shih M.-C., Lu J., Holodniy M., Lavori P. W.; CSP 519 Study Team, Integrating tobacco Cessation into mental health care for posttraumatic stress disorder: A randomized controlled trial. JAMA 304, 2485– 2493 (2010). 21139110 PMC4218733
  67. [89]Krebs P., Rogers E., Smelson D., Fu S., Wang B., Sherman S., Relationship between tobacco cessation and mental health outcomes in a tobacco cessation trial. J. Health Psychol. 23, 1119– 1128 (2018). 27151069
  68. [93]Hurt R. D., Offord K. P., Croghan I. T., Gomez-Dahl L., Kottke T. E., Morse R. M., Melton L. J. III, Mortality following inpatient addictions treatment. Role of tobacco use in a community-based cohort. JAMA 275, 1097– 1103 (1996). 8601929
  69. [94]D. B. Kandel, Stages and Pathways of Drug Involvement: Examining the Gateway Hypothesis (Cambridge Univ. Press, 2002).
  70. [95]Levine A., Huang Y., Drisaldi B., Griffin E. A. Jr., Pollak D. D., Xu S., Yin D., Schaffran C., Kandel D. B., Kandel E. R., Molecular mechanism for a gateway drug: Epigenetic changes initiated by nicotine prime gene expression by cocaine. Sci. Transl. Med. 3, 107ra109 (2011). PMC4042673 22049069
  71. [96]Prochaska J. J., Delucchi K., Hall S. M., A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. J. Consult. Clin. Psychol. 72, 1144– 1156 (2004). 15612860
  72. [97]Liakoni E., Edwards K. C., St. Helen G., Nardone N., Dempsey D. A., Tyndale R. F., Benowitz N. L., Effects of nicotine metabolic rate on withdrawal symptoms and response to cigarette smoking after abstinence. Clin. Pharmacol. Ther. 105, 641– 651 (2019). 30242831 PMC7967935
  73. [101]Rice V. H., Heath L., Livingstone-Banks J., Hartmann-Boyce J., Nursing interventions for smoking cessation. Cochrane Database Syst. Rev. 12, CD001188 (2017). 29243221 PMC6486227
  74. [102]Carr A. B., Ebbert J., Interventions for tobacco cessation in the dental setting. Cochrane Database Syst. Rev., CD005084 (2012). 22696348 PMC3916957
  75. [103]Augustine J. M., Taylor A. M., Pelger M., Schiefer D., Warholak T. L., Smoking quit rates among patients receiving pharmacist-provided pharmacotherapy and telephonic smoking cessation counseling. J. Am. Pharm. Assoc. 56, 129– 136 (2016). 27000162
  76. [104]Quinn V. P., Hollis J. F., Smith K. S., Rigotti N. A., Solberg L. I., Hu W., Stevens V. J., Effectiveness of the 5-As tobacco cessation treatments in nine HMOs. J. Gen. Intern. Med. 24, 149– 154 (2009). 19083066 PMC2628990
  77. [105]Schroeder S. A., What to do with a patient who smokes. JAMA 294, 482– 487 (2005). 16046655
  78. [106]Gordon J. S., Andrews J. A., Crews K. M., Payne T. J., Severson H. H., Lichtenstein E., Do faxed quitline referrals add value to dental office-based tobacco-use cessation interventions? J. Am. Dent. Assoc. 141, 1000– 1007 (2010). 20675426 PMC3780769
  79. [107]Vidrine J. I., Shete S., Li Y., Cao Y., Alford M. H., Galindo-Talton M., Rabius V., Sharp B., Harmonson P., Zbikowski S. M., Miles L., Wetter D. W., The Ask-Advise-Connect approach for smokers in a safety net healthcare system: A group-randomized trial. Am. J. Prev. Med. 45, 737– 741 (2013). 24237916 PMC4023543
  80. [110]Stead L. F., Hartmann-Boyce J., Perera R., Lancaster T., Telephone counselling for smoking cessation. Cochrane Database Syst. Rev., CD002850 (2013). 23934971
  81. [113]Schauer G. L., Malarcher A. M., Zhang L., Engstrom M. C., Zhu S.-H., Prevalence and correlates of quitline awareness and utilization in the United States: An update from the 2009–2010 National Adult Tobacco Survey. Nicotine Tob. Res. 16, 544– 553 (2014). 24253378
  82. [114]Davis K. C., Alexander R. L. Jr., Shafer P., Mann N., Malarcher A., Zhang L., The dose-response relationship between tobacco education advertising and calls to quitlines in the United States, March–June, 2012. Prev. Chronic Dis. 12, E191 (2015). 26542143 PMC4651112
  83. [119]Etter J.-F., A list of the most popular smoking cessation web sites and a comparison of their quality. Nicotine Tob. Res. 8 (suppl. 1), S27– S34 (2006). 17491168
  84. [120]Fraser D., Kobinsky K., Smith S. S., Kramer J., Theobald W. E., Baker T. B., Five population-based interventions for smoking cessation: A MOST trial. Transl. Behav. Med. 4, 382– 390 (2014). 25584087 PMC4286555
  85. [124]Scott-Sheldon L. A. J., Lantini R., Jennings E. G., Thind H., Rosen R. K., Salmoirago-Blotcher E., Bock B. C., Text messaging-based interventions for smoking cessation: A systematic review and meta-analysis. JMIR Mhealth Uhealth 4, e49 (2016). 27207211 PMC4893152
  86. [126]Hoeppner B. B., Hoeppner S. S., Seaboyer L., Schick M. R., Wu G. W. Y., Bergman B. G., Kelly J. F., How smart are smartphone apps for smoking cessation? A content analysis. Nicotine Tob. Res. 18, 1025– 1031 (2016). 26045249 PMC5942604
  87. [129]Prochaska J. J., Pechmann C., Kim R., Leonhardt J. M., Twitter=quitter? An analysis of Twitter quit smoking social networks. Tob. Control 21, 447– 449 (2012). 21730101 PMC3310933
  88. [130]Stoddard J. L., Augustson E. M., Moser R. P., Effect of adding a virtual community (bulletin board) to smokefree.gov: Randomized controlled trial. J. Med. Internet Res. 10, e53 (2008). 19097974 PMC2630832
  89. [131]Pechmann C., Delucchi K., Lakon C. M., Prochaska J. J., Randomised controlled trial evaluation of Tweet2Quit: A social network quit-smoking intervention. Tob. Control 26, 188– 194 (2017). 26928205 PMC5112138
  90. [132]Ramo D. E., Thrul J., Delucchi K. L., Hall S., Ling P. M., Belohlavek A., Prochaska J. J., A randomized controlled evaluation of the tobacco status project, a Facebook intervention for young adults. Addiction 113, 1683– 1695 (2018). PMC6761032 29797621
  91. [133]Thomas J. L., Bengtson J. E., Ghidei W., Schreier M., Wang Q., Luo X., Lust K., Ahluwalia J. S., Social contingencies and college quit and win contest: A qualitative inquiry. Am. J. Health Behav. 39, 232– 241 (2015). 25564836 PMC4704685
  92. [134]Notley C., Gentry S., Livingstone-Banks J., Bauld L., Perera R., Hartmann-Boyce J., Incentives for smoking cessation. Cochrane Database Syst. Rev. 7, CD004307 (2019). 31313293 PMC6635501
  93. [136]Nides M., Danielsson T., Saunders F., Perfekt R., Kapikian R., Solla J., Leischow S. J., Myers A., Efficacy and safety of a nicotine mouth spray for smoking cessation: A randomized, multicenter, controlled study in a naturalistic setting. Nicotine Tob. Res. (2018). 30452732
  94. [138]Benowitz N. L., Burbank A. D., Cardiovascular toxicity of nicotine: Implications for electronic cigarette use. Trends Cardiovasc. Med. 26, 515– 523 (2016). 27079891 PMC4958544
  95. [139]Mills E. J., Thorlund K., Eapen S., Wu P., Prochaska J. J., Cardiovascular events associated with smoking cessation pharmacotherapies: A network meta-analysis. Circulation 129, 28– 41 (2014). 24323793 PMC4258065
  96. [140]Pack Q. R., Priya A., Lagu T. C., Pekow P. S., Atreya A., Rigotti N. A., Lindenauer P. K., Short-term safety of nicotine replacement in smokers hospitalized with coronary heart disease. J. Am. Heart Assoc. 7, e009424 (2018). 30371184 PMC6222950
  97. [143]Anthenelli R. M., Benowitz N. L., West R., St. Aubin L., McRae T., Lawrence D., Ascher J., Russ C., Krishen A., Evins A. E., Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): A double-blind, randomised, placebo-controlled clinical trial. Lancet 387, 2507– 2520 (2016). 27116918
  98. [145]Eisenberg M. J., Windle S. B., Roy N., Old W., Grondin F. R., Bata I., Iskander A., Lauzon C., Srivastava N., Clarke A., Cassavar D., Dion D., Haught H., Mehta S. R., Baril J.-F., Lambert C., Madan M., Abramson B. L., Dehghani P.; EVITA Investigators, Varenicline for smoking cessation in hospitalized patients with acute coronary syndrome. Circulation 133, 21– 30 (2016). 26553744
  99. [146]Rigotti N. A., Pipe A. L., Benowitz N. L., Arteaga C., Garza D., Tonstad S., Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: A randomized trial. Circulation 121, 221– 229 (2010). 20048210 PMC4096941
  100. [147]Benowitz N. L., Pipe A., West R., Hays J. T., Tonstad S., McRae T., Lawrence D., St. Aubin L., Anthenelli R. M., Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers: A randomized clinical trial. JAMA Intern. Med. 178, 622– 631 (2018). 29630702 PMC6145797
  101. [148]Sterling L. H., Windle S. B., Filion K. B., Touma L., Eisenberg M. J., Varenicline and adverse cardiovascular events: A systematic review and meta-analysis of randomized controlled trials. J. Am. Heart Assoc. 5, e002849 (2016). 26903004 PMC4802486
  102. [149]Ebbert J. O., Elrashidi M. Y., Stead L. F., Interventions for smokeless tobacco use cessation. Cochrane Database Syst. Rev., CD004306 (2015). 26501380 PMC6793613
  103. [150]Hays J. T., Hurt R. D., Rigotti N. A., Niaura R., Gonzales D., Durcan M. J., Sachs D. P., Wolter T. D., Buist A. S., Johnston J. A., White J. D., Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized, controlled trial. Ann. Intern. Med. 135, 423– 433 (2001). 11560455
  104. [151]Eisenberg M. J., Grandi S. M., Gervais A., O’Loughlin J., Paradis G., Rinfret S., Sarrafzadegan N., Sharma S., Lauzon C., Yadav R., Pilote L.; ZESCA Investigators, Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: A randomized, placebo-controlled trial. J. Am. Coll. Cardiol. 61, 524– 532 (2013). 23369417
  105. [152]Rigotti N. A., Thorndike A. N., Regan S., McKool K., Pasternak R. C., Chang Y., Swartz S., Torres-Finnerty N., Emmons K. M., Singer D. E., Bupropion for smokers hospitalized with acute cardiovascular disease. Am. J. Med. 119, 1080– 1087 (2006). 17145253
  106. [153]Chang P.-H., Chiang C.-H., Ho W.-C., Wu P.-Z., Tsai J.-S., Guo F.-R., Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: A systematic review and meta-analysis of randomized controlled trials. BMC Public Health 15, 689 (2015). 26198192 PMC4508997
  107. [154]Stead L. F., Perera R., Bullen C., Mant D., Hartmann-Boyce J., Cahill K., Lancaster T., Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. 11, CD000146 (2012). 23152200
  108. [155]Ebbert J. O., Hatsukami D. K., Croghan I. T., Schroeder D. R., Allen S. S., Hays J. T., Hurt R. D., Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: A randomized trial. JAMA 311, 155– 163 (2014). 24399554 PMC3959999
  109. [156]Carpenter M. J., Jardin B. F., Burris J. L., Mathew A. R., Schnoll R. A., Rigotti N. A., Cummings K. M., Clinical strategies to enhance the efficacy of nicotine replacement therapy for smoking cessation: A review of the literature. Drugs 73, 407– 426 (2013). 23572407 PMC3662024
  110. [157]Shiffman S., Ferguson S. G., Nicotine patch therapy prior to quitting smoking: A meta-analysis. Addiction 103, 557– 563 (2008). 18339101
  111. [158]Rennard S., Hughes J., Cinciripini P. M., Kralikova E., Raupach T., Arteaga C., St. Aubin L. B., Russ C.; Flexible Quit Date Study Group, A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. Nicotine Tob. Res. 14, 343– 350 (2012). 22080588 PMC3281242
  112. [159]Sansores R. H., Ramírez-Venegas A., Arellano-Rocha R., Noé-Díaz V., García-Gómez L., Pérez Bautista O., Velázquez Uncal M., Use of varenicline for more than 12 months for smoking cessation in heavy chronic obstructive pulmonary disease smokers unmotivated to quit: A pilot study. Ther. Adv. Respir. Dis. 10, 383– 390 (2016). 27352612 PMC5933615
  113. [160]Lindson N., Aveyard P., Hughes J. R., Reduction versus abrupt cessation in smokers who want to quit. Cochrane Database Syst. Rev., CD008033 (2010). 20238361
  114. [161]Ebbert J. O., Hughes J. R., West R. J., Rennard S. I., Russ C., McRae T. D., Treadow J., Yu C.-R., Dutro M. P., Park P. W., Effect of varenicline on smoking cessation through smoking reduction: A randomized clinical trial. JAMA 313, 687– 694 (2015). 25688780 PMC4883651
  115. [162]Dempsey D., Tutka P., Jacob P. III, Allen F., Schoedel K., Tyndale R. F., Benowitz N. L., Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin. Pharmacol. Ther. 76, 64– 72 (2004). 15229465
  116. [163]St. Helen G., Jacob P. III, Benowitz N. L., Stability of the nicotine metabolite ratio in smokers of progressively reduced nicotine content cigarettes. Nicotine Tob. Res. 15, 1939– 1942 (2013). 23674838 PMC3790625
  117. [164]Lerman C., Schnoll R. A., Hawk L. W. Jr., Cinciripini P., George T. P., Wileyto E. P., Swan G. E., Benowitz N. L., Heitjan D. F., Tyndale R. F., Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: A randomised, double-blind placebo-controlled trial. Lancet Respir. Med. 3, 131– 138 (2015). 25588294 PMC4480925
  118. [165]Tutka P., Vinnikov D., Courtney R. J., Benowitz N. L., Cytisine for nicotine addiction treatment: A review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation. Addiction, (2019). 31240783
  119. [166]Gourlay S. G., Stead L. F., Benowitz N. L., Clonidine for smoking cessation. Cochrane Database Syst. Rev., CD000058 (2004). 15266422 PMC7038651
  120. [167]Hughes J. R., Stead L. F., Lancaster T., Nortriptyline for smoking cessation: A review. Nicotine Tob. Res. 7, 491– 499 (2005). 16085520
  121. [168]Gómez-Coronado N., Walker A. J., Berk M., Dodd S., Current and emerging pharmacotherapies for cessation of tobacco smoking. Pharmacotherapy 38, 235– 258 (2018). 29250815
  122. [169]Shanahan W. R., Rose J. E., Glicklich A., Stubbe S., Sanchez-Kam M., Lorcaserin for smoking cessation and associated weight gain: A randomized 12-week clinical trial. Nicotine Tob. Res. 19, 944– 951 (2017). 27815511
  123. [170]Hartmann-Boyce J., Begh R., Aveyard P., Electronic cigarettes for smoking cessation. BMJ 360, j5543 (2018). 29343486
  124. [171]Hajek P., Phillips-Waller A., Przulj D., Pesola F., Myers Smith K., Bisal N., Li J., Parrott S., Sasieni P., Dawkins L., Ross L., Goniewicz M., Wu Q., McRobbie H. J., A randomized trial of e-cigarettes versus nicotine-replacement therapy. N. Engl. J. Med. 380, 629– 637 (2019). 30699054
  125. [172]Yong H.-H., Hitchman S. C., Cummings K. M., Borland R., Gravely S. M. L., McNeill A., Fong G. T., Does the regulatory environment for e-cigarettes influence the effectiveness of e-cigarettes for smoking cessation?: Longitudinal findings from the ITC Four Country Survey. Nicotine Tob. Res. 19, 1268– 1276 (2017). 28340053 PMC5896424
  126. [173]Zhu S.-H., Zhuang Y.-L., Wong S., Cummins S. E., Tedeschi G. J., E-cigarette use and associated changes in population smoking cessation: Evidence from US current population surveys. BMJ 358, j3262 (2017). 28747333 PMC5526046
  127. [174]Brown J., Beard E., Kotz D., Michie S., West R., Real-world effectiveness of e-cigarettes when used to aid smoking cessation: A cross-sectional population study. Addiction 109, 1531– 1540 (2014). 24846453 PMC4171752
  128. [175]A. McNeill, L. S. Brose, R. Calder, L. Bauld, D. Robson, Evidence Review of E-Cigarettes and Heated Tobacco Products 2018. A Report Comissioned by Public Health England (Public Health England, 2018), p. 243.
  129. [176]Kalkhoran S., Chang Y., Rigotti N. A., Electronic cigarette use and cigarette abstinence over 2 years among U.S. smokers in the population assessment of tobacco and health study. Nicotine Tob. Res., (2019). PMC7171267 31298296
  130. [177]Hitchman S. C., Brose L. S., Brown J., Robson D., McNeill A., Associations between e-cigarette type, frequency of use, and quitting smoking: Findings from a longitudinal online panel survey in Great Britain. Nicotine Tob. Res. 17, 1187– 1194 (2015). 25896067 PMC4580313
  131. [178]Gomajee R., El-Khoury F., Goldberg M., Zins M., Lemogne C., Wiernik E., Lequy-Flahault E., Romanello L., Kousignian I., Melchior M., Association between electronic cigarette use and smoking reduction in France. JAMA Intern. Med. 179, 1193– 1200 (2019). PMC6632120 31305860
  132. [179]Holmes C. B., King B. A., Babb S. D., Stuck in neutral: Stalled progress in statewide comprehensive smoke-free laws and cigarette excise taxes, United States, 2000-2014. Prev. Chronic Dis. 13, E80 (2016). 27309417 PMC4927266
  133. [180]Ribisl K. M., Luke D. A., Henriksen L., The case for a concerted push to reduce place-based disparities in smoking-related cancers. JAMA Intern. Med. 176, 1799– 1800 (2016). 27775767 PMC5517298
  134. [181]Luke D. A., Sorg A. A., Combs T., Robichaux C. B., Moreland-Russell S., Ribisl K. M., Henriksen L., Tobacco retail policy landscape: A longitudinal survey of US states. Tob. Control 25, i44– i51 (2016). 27697947 PMC5099223
  135. [182]Durkin S., Brennan E., Wakefield M., Mass media campaigns to promote smoking cessation among adults: An integrative review. Tob. Control 21, 127– 138 (2012). 22345235
  136. [183]National Cancer Institute, The Role of the Media in Promoting and Reducing Tobacco Use. Tobacco Control Monograph Series (U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, 2008), vol. 19.
  137. [184]Murphy-Hoefer R., Davis K. C., Beistle D., King B. A., Duke J., Rodes R., Graffunder C., Impact of the Tips From Former Smokers campaign on population-level smoking cessation, 2012-2015. Prev. Chronic Dis. 15, E71 (2018). 29862960 PMC5985905
  138. [185]Prochaska J. J., Gates E., Davis K., Gutierrez K., Beistle D., Hunt Y., Armour B., Rodes R., The 2016 tips from former smokers® campaign: Associations with quit intentions and quit attempts among smokers with and without mental health conditions. Nicotine Tob. Res. 21, 576– 583 (2019). 30496491 PMC6615317
  139. [186]Farrelly M. C., Duke J. C., Nonnemaker J., MacMonegle A. J., Alexander T. N., Zhao X., Delahanty J. C., Rao P., Allen J. A., Association between The Real Cost media campaign and smoking initiation among youths—United States, 2014–2016. Morb. Mortal. Wkly. Rep. 66, 47– 50 (2017). PMC5657653 28103214
  140. [188]Ong M. K., Zhou Q., Sung H. Y., Sensitivity to cigarette prices among individuals with alcohol, drug, or mental disorders. Am. J. Public Health 100, 1243– 1245 (2010). 20466972 PMC2882416
  141. [189]Friedman A. S., Schpero W. L., Busch S. H., Evidence suggests that the ACA's tobacco surcharges reduced insurance take-up and did not increase smoking cessation. Health Aff. 35, 1176– 1183 (2016). PMC5589079 27385231
  142. [193]Smith P. H., Young-Wolff K. C., Hyland A., McKee S. A., Are statewide restaurant and bar smoking bans associated with reduced cigarette smoking among those with mental illness? Nicotine Tob. Res. 16, 846– 854 (2014). 24566280 PMC4015101
  143. [194]Institute of Medicine, Public Health Implications of Raising the Minimum Age of Legal Access to Tobacco Products, R. J. Bonnie, K. Stratton, L. Y. Kwan, Eds. (The National Academies Press, 2015). 26269869
  144. [195]Leas E. C., Schliecher N., Recinos A., Mahoney M., Henriksen L., State and regional gaps in coverage of ‘Tobacco 21’ policies. Tob. Control, (2019). PMC7365022 31004006
  145. [196]Friedman A. S., Wu R. J., Do local Tobacco-21 laws reduce smoking among 18 to 20 year-olds? Nicotine Tob. Res., (2019). 31348515
  146. [197]Winickoff J. P., McMillen R., Tanski S., Wilson K., Gottlieb M., Crane R., Public support for raising the age of sale for tobacco to 21 in the United States. Tob. Control 25, 284– 288 (2016). 25701856
  147. [198]Lee J. G., Boynton M. H., Richardson A., Jarman K., Ranney L. M., Goldstein A. O., Raising the legal age of tobacco sales: Policy support and trust in government, 2014-2015 U.S. Am. J. Prev. Med. 51, 910– 915 (2016). 27263054 PMC5116423
  148. [200]Lee J. G., Sun D. L., Schleicher N. M., Ribisl K. M., Luke D. A., Henriksen L., Inequalities in tobacco outlet density by race, ethnicity and socioeconomic status, 2012, USA: Results from the ASPiRE Study. J. Epidemiol. Community Health 71, 487– 492 (2017). 28249990 PMC5458784
  149. [201]Henriksen L., Andersen-Rodgers E., Zhang X., Roeseler A., Sun D. L., Johnson T. O., Schleicher N. C., Neighborhood variation in the price of cheap tobacco products in California: Results from healthy stores for a healthy community. Nicotine Tob. Res. 19, 1330– 1337 (2017). 28444233 PMC5896445
  150. [202]Institute of Medicine, Ending the Tobacco Problem: A Blueprint for the Nation. Committee on Reducing Tobacco Use: Strategies, Barriers, and Consequences (The National Academies Press, 2007).
  151. [204]Shang C., Huang J., Cheng K.-W., Li Q., Chaloupka F. J., Global evidence on the association between POS advertising bans and youth smoking participation. Int. J. Environ. Res. Public Health 13, E306 (2016). 27005651 PMC4808969
  152. [205]Tabuchi T., Gallus S., Shinozaki T., Nakaya T., Kunugita N., Colwell B., Heat-not-burn tobacco product use in Japan: Its prevalence, predictors and perceived symptoms from exposure to secondhand heat-not-burn tobacco aerosol. Tob. Control 27, e25– e33 (2018). 29248896 PMC6073918
  153. [206]Mejia A. B., Ling P. M., Glantz S. A., Quantifying the effects of promoting smokeless tobacco as a harm reduction strategy in the USA. Tob. Control 19, 297– 305 (2010). 20581427 PMC3102305
  154. [207]Zeller M., Hatsukami D.; Strategic Dialogue on Tobacco Harm Reduction Group, The strategic dialogue on tobacco harm reduction: A vision and blueprint for action in the US. Tob. Control 18, 324– 332 (2009). 19240228 PMC4915216
  155. [208]Boffetta P., Hecht S., Gray N., Gupta P., Straif K., Smokeless tobacco and cancer. Lancet Oncol. 9, 667– 675 (2008). 18598931
  156. [209]Levy D. T., Mumford E. A., Cummings K. M., Gilpin E. A., Giovino G., Hyland A., Sweanor D., Warner K. E., The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: Estimates of a panel of experts. Cancer Epidemiol. Biomarkers Prev. 13, 2035– 2042 (2004). 15598758
  157. [210]Rutqvist L. E., Curvall M., Hassler T., Ringberger T., Wahlberg I., Swedish snus and the GothiaTek® standard. Harm Reduct. J. 8, 11 (2011). 21575206 PMC3119032
  158. [211]Ramstrom L., Borland R., Wikmans T., Patterns of smoking and snus use in Sweden: Implications for public health. Int. J. Environ. Res. Public Health 13, E1110 (2016). 27834883 PMC5129320
  159. [212]Kozlowski L. T., Sweanor D. T., Young or adult users of multiple tobacco/nicotine products urgently need to be informed of meaningful differences in product risks. Addict. Behav. 76, 376– 381 (2018). 28148394
  160. [213]Hatsukami D. K., Severson H., Anderson A., Vogel R. I., Jensen J., Broadbent B., Murphy S. E., Carmella S., Hecht S. S., Randomised clinical trial of snus versus medicinal nicotine among smokers interested in product switching. Tob. Control 25, 267– 274 (2016). 25991608 PMC4785094
  161. [214]Nelson P. R., Chen P., Battista D. R., Pillitteri J. L., Shiffman S., Randomized trial to compare smoking cessation rates of snus, with and without smokeless tobacco health-related information, and a nicotine lozenge. Nicotine Tob. Res. 21, 88– 94 (2019). 29373698 PMC6302352
  162. [215]Borland R., Murray K., Gravely S., Fong G. T., Thompson M. E., McNeill A., O'Connor R. J., Goniewicz M. L., Yong H.-H., Levy D. T., Heckman B. W., Cummings K. M., A new classification system for describing concurrent use of nicotine vaping products alongside cigarettes (so-called ‘dual use’): Findings from the ITC-4 Country Smoking and Vaping wave 1 Survey. Addiction 2019, 14570 (2019). PMC6669110 30702175
  163. [216]Schauer G. L., Pederson L. L., Malarcher A. M., Past year quit attempts and use of cessation resources among cigarette-only smokers and cigarette smokers who use other tobacco products. Nicotine Tob. Res. 18, 41– 47 (2016). 25744953 PMC5896792
  164. [218]de Dios M. A., Vaughan E. L., Stanton C. A., Niaura R., Adolescent tobacco use and substance abuse treatment outcomes. J. Subst. Abuse Treat. 37, 17– 24 (2009). 19004603 PMC2735078
  165. [219]Moore B. A., Budney A. J., Abstinence at intake for marijuana dependence treatment predicts response. Drug Alcohol Depend. 67, 249– 257 (2002). 12127196
  166. [220]Fairman B. J., Cannabis problem experiences among users of the tobacco-cannabis combination known as blunts. Drug Alcohol Depend. 150, 77– 84 (2015). 25746234 PMC4387065
  167. [221]Meier E., Hatsukami D. K., A review of the additive health risk of cannabis and tobacco co-use. Drug Alcohol Depend. 166, 6– 12 (2016). 27476751
  168. [223]Prochaska J. J., Epperson A., Skan J., Oppezzo M., Barnett P., Delucchi K., Schnellbaecher M., Benowitz N. L., The Healing and Empowering Alaskan Lives Toward Healthy-Hearts (HEALTHH) project: Study protocol for a randomized controlled trial of an intervention for tobacco use and other cardiovascular risk behaviors for Alaska Native People. Contemp. Clin. Trials 71, 40– 46 (2018). 29864548 PMC6636857
  169. [224]Higgins S. T., Kurti A. N., Palmer M., Tidey J. W., Cepeda-Benito A., Cooper M. R., Krebs N. M., Baezconde-Garbanati L., Hart J. L., Stanton C. A., A review of tobacco regulatory science research on vulnerable populations. Prev. Med., 105709 (2019). 31054904 PMC6824984
  170. [225]Benowitz N. L., Henningfield J. E., Establishing a nicotine threshold for addiction. The implications for tobacco regulation. N. Engl. J. Med 331, 123– 125 (1994). 7818638
  171. [226]Donny E. C., Denlinger R. L., Tidey J. W., Koopmeiners J. S., Benowitz N. L., Vandrey R. G., al'Absi M., Carmella S. G., Cinciripini P. M., Dermody S. S., Drobes D. J., Hecht S. S., Jensen J., Lane T., Le C. T., McClernon F. J., Montoya I. D., Murphy S. E., Robinson J. D., Stitzer M. L., Strasser A. A., Tindle H., Hatsukami D. K., Randomized trial of reduced-nicotine standards for cigarettes. N. Engl. J. Med. 373, 1340– 1349 (2015). 26422724 PMC4642683
  172. [227]Hatsukami D. K., Kotlyar M., Hertsgaard L. A., Zhang Y., Carmella S. G., Jensen J. A., Allen S. S., Shields P. G., Murphy S. E., Stepanov I., Hecht S. S., Reduced nicotine content cigarettes: Effects on toxicant exposure, dependence and cessation. Addiction 105, 343– 355 (2010). 20078491 PMC4565618
  173. [228]Benowitz N. L., Nardone N., Dains K. M., Hall S. M., Stewart S., Dempsey D., Jacob P 3rd, Effect of reducing the nicotine content of cigarettes on cigarette smoking behavior and tobacco smoke toxicant exposure: 2-year follow up. Addiction 110, 1667– 1675 (2015). 26198394 PMC4565734
  174. [229]Nardone N., Donny E. C., Hatsukami D. K., Koopmeiners J. S., Murphy S. E., Strasser A. A., Tidey J. W., Vandrey R., Benowitz N. L., Estimations and predictors of non-compliance in switchers to reduced nicotine content cigarettes. Addiction 111, 2208– 2216 (2016). 27367436 PMC5203964
  175. [230]Mercincavage M., Wileyto E. P., Saddleson M. L., Lochbuehler K., Donny E. C., Strasser A. A., Attrition during a randomized controlled trial of reduced nicotine content cigarettes as a proxy for understanding acceptability of nicotine product standards. Addiction 112, 1095– 1103 (2017). 28107596 PMC5407938
  176. [231]AhnAllen C. G., Bidwell L. C., Tidey J. W., Cognitive effects of very low nicotine content cigarettes, with and without nicotine replacement, in smokers with schizophrenia and controls. Nicotine Tob. Res. 17, 510– 514 (2015). 25143294 PMC4402354
  177. [234]Levy D. T., Borland R., Lindblom E. N., Goniewicz M. L., Meza R., Holford T. R., Yuan Z., Luo Y., O'Connor R. J., Niaura R., Abrams D. B., Potential deaths averted in USA by replacing cigarettes with e-cigarettes. Tob. Control 27, 18– 25 (2018). 28970328 PMC5801653
  178. [235]Rubinstein M. L., Delucchi K., Benowitz N. L., Ramo D. E., Adolescent exposure to toxic volatile organic chemicals from e-cigarettes. Pediatrics 141, e20173557 (2018). 29507165 PMC5869331

Cited by

Sorted by citations

Authors
Prochaska, J. J., & Benowitz, N. L.
Affiliations
  • Stanford Medicine (US)
  • University of California, San Francisco (US)
Corresponding author
Prochaska, Judith J.
ORCID
Venue
Science Advances
Publisher
American Association for the Advancement of Science (AAAS)
Published
2019-10-11
Volume
5
Issue
10
Pages
eaay9763-eaay9763
ISSN
2375-2548 (ISSN-L)
DOI
10.1126/sciadv.aay9763
PMC
PMC6795520
OpenAlex
W2981148845
Cited by
219
References
30
Citations by year
2026: 25 · 2025: 31 · 2024: 38 · 2023: 37 · 2022: 32 · 2021: 40 · 2020: 13 · 2019: 1 · 2017: 1
FWCI
2.52
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Science Advances (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
Funders
  • National Heart, Lung, and Blood Institute (R01HL117736, #U54HL147127)
  • National Cancer Institute (#P01CA225597)
Topics
  • Health Sciences › Medicine › Physiology › Smoking Behavior and Cessation
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
Keywords
nicotine dependence, smoking cessation, tobacco harm reduction, electronic cigarettes, heated tobacco products, smokeless tobacco, tobacco dependence treatment, behavioral addiction, combustible cigarettes
MeSH terms
Animals, Humans, Nicotine, Smoking, Tobacco Use Disorder, Tobacco Products

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review